[go: up one dir, main page]

DK3016527T3 - Behandling af fedme, det metaboliske syndrom, type-2 diabetes, kardiovaskulære sygdomme, demens, alzheimers sygdom og inflammatorisk tarmsygdom ved anvendelse af mindst én bakteriestamme fra prevotella - Google Patents

Behandling af fedme, det metaboliske syndrom, type-2 diabetes, kardiovaskulære sygdomme, demens, alzheimers sygdom og inflammatorisk tarmsygdom ved anvendelse af mindst én bakteriestamme fra prevotella Download PDF

Info

Publication number
DK3016527T3
DK3016527T3 DK14808269.6T DK14808269T DK3016527T3 DK 3016527 T3 DK3016527 T3 DK 3016527T3 DK 14808269 T DK14808269 T DK 14808269T DK 3016527 T3 DK3016527 T3 DK 3016527T3
Authority
DK
Denmark
Prior art keywords
product
disease
diabetes
type
alzheimer
Prior art date
Application number
DK14808269.6T
Other languages
English (en)
Inventor
Inger Björck
Anne Nilsson
Petia Kovatcheva-Datchary
Fredrick Bäckhed
Original Assignee
Proprev Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52008426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3016527(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Proprev Ab filed Critical Proprev Ab
Application granted granted Critical
Publication of DK3016527T3 publication Critical patent/DK3016527T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/02—Products made from whole meal; Products containing bran or rough-ground grain
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/04—Products made from materials other than rye or wheat flour
    • A21D13/047—Products made from materials other than rye or wheat flour from cereals other than rye or wheat, e.g. rice
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/06—Products with modified nutritive value, e.g. with modified starch content
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/06—Products with modified nutritive value, e.g. with modified starch content
    • A21D13/062—Products with modified nutritive value, e.g. with modified starch content with modified sugar content; Sugar-free products
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/40—Products characterised by the type, form or use
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/40—Products characterised by the type, form or use
    • A21D13/42—Tortillas
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/40—Products characterised by the type, form or use
    • A21D13/43—Flatbreads, e.g. naan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (15)

1. Produkt til brug i behandlingen af fedme, det metaboliske syndrom, type-2 diabetes, kardiovaskulære sygdomme, demens, Alzheimers sygdom og inflammatorisk tarmsygdom omfattende mindst én isoleret bakteriestamme fra arterne Prevotellaceae, hvori stammen er valgt fa gruppen bestående af Prevotella copri og Prevotella ruminicola.
2. Produkt til brug i behandlingen af fedme, det metaboliske syndrom, type-2 diabetes, kardiovaskulære sygdomme, demens, Alzheimers sygdom og inflammatorisk tarmsygdom ifølge krav 1, hvori produktet omfatter Prevotella copri.
3. Produkt til brug i behandlingen af fedme, det metaboliske syndrom, type-2 diabetes, kardiovaskulære sygdomme, demens, Alzheimers sygdom og inflammatorisk tarmsygdom ifølge et hvilket som helst af kravene 1-2, hvori produktet omfatter mindst én type kostfibre.
4. Produkt til brug i behandlingen af fedme, det metaboliske syndrom, type-2 diabetes, kardiovaskulære sygdomme, demens, Alzheimers sygdom og inflammatorisk tarmsygdom ifølge krav 3, hvori produktet omfatter mindst én resistent stivelse.
5. Produkt til brug i behandlingen af fedme, det metaboliske syndrom, type-2 diabetes, kardiovaskulære sygdomme, demens, Alzheimers sygdom og inflammatorisk tarmsygdom ifølge et hvilket som helst af de foregående krav, hvori bakteriestammen er genetisk modificeret.
6. Produkt til brug i behandlingen af fedme, det metaboliske syndrom, type-2 diabetes, kardiovaskulære sygdomme, demens, Alzheimers sygdom og inflammatorisk tarmsygdom ifølge et hvilket som helst af kravene 1-5, hvori kostfibrene og den resistente stivelse er relateret til cerealer i enhver form som f.eks. byg-, hvede-, rug-, havre-fibre, beta-glucan.
7. Produkt til brug i behandlingen af fedme, det metaboliske syndrom, type-2 diabetes, kardiovaskulære sygdomme, demens, Alzheimers sygdom og inflammatorisk tarmsygdom ifølge krav 6, hvori kostfiberen er fra byg.
8. Produkt til brug i behandlingen af fedme, det metaboliske syndrom, type-2 diabetes, kardiovaskulære sygdomme, demens, Alzheimers sygdom og inflammatorisk tarmsygdom ifølge et hvilket som helst af kravene 1-7, hvori den resistente stivelse er i enhver form som f.eks. iboende i bygkerner, retrograd stivelse, botanisk indkapslet stivelse, nativ ugelatiniseret stivelse, cyclo-dextriner eller kemisk modificeret stivelse.
9. Produkt til brug i behandlingen af fedme, det metaboliske syndrom, type-2 diabetes, kardiovaskulære sygdomme, demens, Alzheimers sygdom og inflammatorisk tarmsygdom ifølge et hvilket som helst af kravene 1-8, omfattende en yderligere bakteriestamme, hvori stammen er en succinatproducerende stamme.
10. Produkt til brug i behandlingen af fedme, det metaboliske syndrom, type-2 diabetes, kardiovaskulære sygdomme, demens, Alzheimers sygdom og inflammatorisk tarmsygdom ifølge et hvilket som helst af kravene 1-9 omfattende succinat.
11. Produkt til brug i behandlingen af fedme, det metaboliske syndrom, type-2 diabetes, kardiovaskulære sygdomme, demens, Alzheimers sygdom og inflammatorisk tarmsygdom ifølge et hvilket som helst af kravene 1-10, hvori bakteriestammen fra arterne Prevotellaceae er indkapslet eller lyofiliseret.
12. Produkt omfattende mindst én isoleret bakteriestamme fra arterne Prevotellaceae, hvori stammen er valgt fra gruppen bestående af Prevotella copri og Prevotella ruminicola, og hvori produktet yderligere omfatter mindst én type af kostfibre.
13. Produkt ifølge krav 12, hvori produktet, som den eneste bakteriestamme, omfatter én isoleret bakteriestamme fra arterne Prevotellaceae, hvori stammen er Prevotella copri.
14. Produkt ifølge krav 12, hvori produktet yderligere omfatter en yderligere bakteriestamme, hvori stammen er en succinatproducerende stamme.
15. Produkt ifølge et hvilket som helst af kravene 12-14, hvori produktet yderligere omfatter succinat.
DK14808269.6T 2013-06-03 2014-05-27 Behandling af fedme, det metaboliske syndrom, type-2 diabetes, kardiovaskulære sygdomme, demens, alzheimers sygdom og inflammatorisk tarmsygdom ved anvendelse af mindst én bakteriestamme fra prevotella DK3016527T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1350675 2013-06-03
PCT/SE2014/050650 WO2014196913A1 (en) 2013-06-03 2014-05-27 Treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimer's disease and inflammatory bowel disease by using at least one bacterial strain from prevotella

Publications (1)

Publication Number Publication Date
DK3016527T3 true DK3016527T3 (da) 2018-11-12

Family

ID=52008426

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14808269.6T DK3016527T3 (da) 2013-06-03 2014-05-27 Behandling af fedme, det metaboliske syndrom, type-2 diabetes, kardiovaskulære sygdomme, demens, alzheimers sygdom og inflammatorisk tarmsygdom ved anvendelse af mindst én bakteriestamme fra prevotella

Country Status (10)

Country Link
US (3) US10137157B2 (da)
EP (1) EP3016527B1 (da)
CN (1) CN105451576B (da)
DK (1) DK3016527T3 (da)
ES (1) ES2692162T3 (da)
PL (1) PL3016527T3 (da)
PT (1) PT3016527T (da)
SG (1) SG11201510750XA (da)
TR (1) TR201815566T4 (da)
WO (1) WO2014196913A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170100328A1 (en) * 2011-02-04 2017-04-13 Joseph E. Kovarik Bioadhesive Strip and Method of Using Same
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
EP2932424A2 (en) * 2012-12-13 2015-10-21 Metabogen AB Identification of a person having risk for developing type 2 diabetes
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
CN106663137B (zh) 2014-04-28 2020-07-10 耶达研究及发展有限公司 用于预测对食物的反应的方法和装置
FI127671B (en) 2014-05-28 2018-11-30 Filip Scheperjans Method for diagnostics of Parkinson’s disease
WO2016110768A1 (en) * 2015-01-07 2016-07-14 Ecole Polytechnique Federale De Lausanne (Epfl) Gastro-intestinal biomarkers for diagnosis and therapies of proteinopathies
BR112017024928A2 (pt) * 2015-05-21 2018-07-31 Yeda Research And Development Co Ltd Métodos para prevenção da diabetes ou pré- diabetes em um indivíduo, para melhoria da resposta à glicose em um indivíduo com intolerância à glicose, para manutenção da resposta à glicose em um indivíduo com tolerância à glicose e para melhoria da saúde de um indivíduo, composição probiótica e composição farmacêutica
US11529380B2 (en) 2016-12-23 2022-12-20 MURDOCH CHILDREN'S RESEARCH INSTITUTE Parkville Methods and compositions for determining, and for minimizing, the likelihood of development of allergy in infants
WO2018136884A1 (en) * 2017-01-23 2018-07-26 The Regents Of The University Of California Compositions and methods for treating obesity and inducing weight loss
EP3369423A1 (en) * 2017-03-01 2018-09-05 Reminisciences Synbiotic composition and its use for preventing and/or treating neurodegenerative disorders
JP7369690B2 (ja) * 2017-09-08 2023-10-26 エヴェロ バイオサイエンシズ，インコーポレーテッド 細菌の細胞外小胞
CN111526881A (zh) * 2017-09-08 2020-08-11 伊夫罗生物科学公司 来自普雷沃菌的胞外囊泡
WO2019168990A1 (en) 2018-02-27 2019-09-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Probiotics and probiotic compositions for regulating body weight
KR102118993B1 (ko) * 2018-03-06 2020-06-05 주식회사 엠디헬스케어 프레보텔라 속 세균 유래 나노소포 및 이의 용도
CN110638838B (zh) * 2018-06-26 2021-07-06 瑞微（深圳）生物科技有限公司 阿克曼粘细菌或普氏菌在制备用于增强抗肿瘤免疫功能的药物中的应用
EP3840761A4 (en) * 2018-08-20 2022-05-18 Murdoch Children's Research Institute BEHAVIORAL TREATMENT
US20220031765A1 (en) 2018-11-30 2022-02-03 Ospedale San Raffaele S.R.L. Bacterial strains for medical uses
CN111450124B (zh) * 2019-01-18 2022-03-15 瑞微（深圳）生物科技有限公司 阿克曼粘菌或普氏菌在增加肿瘤微环境γδT细胞积累并增强抗肿瘤免疫功能药物中的应用
WO2020176624A1 (en) * 2019-02-26 2020-09-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Probiotics and probiotic compositions having modified carbohydrate metabolism
BR112021025676A2 (pt) * 2019-06-21 2022-05-17 Evelo Biosciences Inc Composições e métodos para tratar uma afecção mediada por th2 com o uso de prevotella
JP2023542447A (ja) * 2020-04-03 2023-10-10 デュポン ニュートリション バイオサイエンシス エーピーエス 代謝の健康を改善するための細菌株を含む組成物
CA3186466A1 (en) * 2020-07-21 2022-01-27 Mark BODMER Prevotella histicola strain c as an oral therapy for inflammatory diseases
WO2022061119A1 (en) * 2020-09-21 2022-03-24 Evelo Biosciences, Inc. Compositions and methods for modulating immune responses with prevotella histicola
KR102789055B1 (ko) * 2021-02-03 2025-03-31 국민대학교 산학협력단 장내 미생물 또는 이로부터 유래된 세포밖 소포체를 유효성분으로 포함하는 수면장애의 예방, 개선 또는 치료용 조성물
EP4440342A1 (en) * 2021-12-02 2024-10-09 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
US20250255909A1 (en) * 2022-04-14 2025-08-14 Washington University Prevotella copri formulations and methods of use
CN117187342B (zh) * 2022-09-27 2024-07-26 合肥瀚微生物科技有限公司 一种基于质谱检测肠道内单个细菌代谢物的方法
WO2025088114A1 (en) * 2023-10-27 2025-05-01 Compagnie Gervais Danone Cereal bases and methods for their production
CN118806799B (zh) * 2024-06-11 2025-07-22 中南大学 普雷沃氏菌在制备治疗或辅助治疗高血压的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
EP1384483A1 (en) 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
US20120076895A1 (en) 2009-04-23 2012-03-29 Bacterfield Ou Extruded food products comprising probiotic micro-organisms
WO2011053653A2 (en) * 2009-10-30 2011-05-05 Mayo Foundation For Medical Education And Research Prevotella histicola preparations and the treatment of autoimmune conditions
MX2013007736A (es) 2010-12-29 2013-07-24 Nestec Sa Una composicion nutricional que comprende fibra y probioticos para reducir sintomas intestinales relacionados con estres.
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
CN102744320B (zh) * 2011-04-21 2014-11-19 中国北车集团大同电力机车有限责任公司 冲压模具
WO2013053836A1 (en) * 2011-10-11 2013-04-18 Quantum Pharmaceuticals Sa Composition comprising anaerobically cultivated human intestinal microbiota
CN102743420A (zh) * 2012-06-06 2012-10-24 上海交通大学 改善肠道菌群结构的方法及应用

Also Published As

Publication number Publication date
US12370226B2 (en) 2025-07-29
EP3016527A1 (en) 2016-05-11
ES2692162T3 (es) 2018-11-30
US20190151376A1 (en) 2019-05-23
EP3016527A4 (en) 2017-03-15
SG11201510750XA (en) 2016-02-26
WO2014196913A1 (en) 2014-12-11
US20160113972A1 (en) 2016-04-28
US20240285695A1 (en) 2024-08-29
CN105451576A (zh) 2016-03-30
CN105451576B (zh) 2020-07-14
PT3016527T (pt) 2018-11-09
US10137157B2 (en) 2018-11-27
PL3016527T3 (pl) 2019-02-28
WO2014196913A9 (en) 2017-03-02
HK1218839A1 (zh) 2017-03-17
EP3016527B1 (en) 2018-07-25
TR201815566T4 (tr) 2018-11-21

Similar Documents

Publication Publication Date Title
US12370226B2 (en) Prevotella copri compositions
Binns Probiotics, prebiotics and the gut microbiota.
Patel et al. The current trends and future perspectives of prebiotics research: a review
JP7330667B2 (ja) ゴールドキウイフルーツ組成物ならびにその調製および使用方法
US20060093592A1 (en) Synbiotics
Siva et al. Lentil (Lens culinaris Medikus) diet affects the gut microbiome and obesity markers in rat
Wang et al. Dietary intervention with α-amylase inhibitor in white kidney beans added yogurt modulated gut microbiota to adjust blood glucose in mice
CN104519895A (zh) 霞多丽种子产品的治疗用途
CN101772308A (zh) 益生菌和纤维在腹泻上的应用
Ray Lactic acid bacteria in food biotechnology: innovations and functional aspects
Voss et al. Interplay between probiotics and prebiotics for human nutrition and health
US20220241353A1 (en) Prebiotic and probiotic cookie preparation
Depeint et al. Bifidogenic effect of a wheat arabinoxylan (MC-AX) is observed across two animal models, a simulated human intestine model (SHIME®) and a clinical study
WO2021003073A1 (en) Prebiotic and probiotic cookie preparation
WO2021023844A1 (en) Compositions and methods for predicting and promoting weight loss in patients with low amy1 copy numbers
HK1218839B (zh) 通过使用来自普雷沃氏菌属的至少一种细菌菌株治疗肥胖、代谢综合征、2型糖尿病、心血管疾病、痴呆、阿尔茨海默病和炎性肠病
Rios-Covián et al. Short-chain fatty acids and human nutrition
Jana et al. Probiotics and prebiotics, including fibers and medicinal foods
JP2020129986A (ja) 経口組成物
Smith Effect of Processing on Microbiota Accessible Carbohydrates in Whole Grains
US20210401737A1 (en) Prebiotic and probiotic cookie preparation
Figueiredo Avaliação de diferentes prebióticos, probióticos e seus metabólitos na inibição de bactérias patogênicas e potenciais aplicações na preservação de alimentos e benefícios à saúde.
Shinde Synbiotic efficacy of probiotic and prebiotic food ingredients for gut health
Hota et al. Screening of prebiotics from Jhargram tribal biodiversity.
Keerthi et al. Enzymes in Probiotics